Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | AGXT | P21549 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6460557 | 0.84 | ENPP2 (0.37) | ENPP2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL1138295 | 0.83 | ENPP2 (0.38) | ENPP2IDO1AGXTMGLLHTR2C | |
| SCHEMBL3984743 | 0.82 | ACHE (0.38) | ENPP2IDO1AGXTMGLLCES2 | |
| SCHEMBL4832669 | 0.81 | CYP2D6 (0.35) | ENPP2IDO1AGXTKMT2A | |
| SCHEMBL4940661 | 0.81 | ALDH1A1 (0.50) | ENPP2KDM4EALDH1A1 | |
| SCHEMBL3999045 | 0.80 | ORAI1 (0.43) | — | |
| SCHEMBL1138975 | 0.79 | ALDH1A1 (0.42) | ENPP2IDO1MGLLKDM4EALDH1A1 | |
| SCHEMBL3658498 | 0.78 | IDO1 (0.40) | ENPP2IDO1AGXTMGLL | |
| SCHEMBL1138531 | 0.77 | ENPP2 (0.54) | ENPP2ALDH1A1 | |
| SCHEMBL1138363 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765358-B1 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | ANACOR PHARMACEUTICALS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7888356-B2 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7652000-B2 | Boron-containing compounds and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1765360-B1 | ANTI-VIRAL USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS INC (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2044091-A2 | COMPOUNDS FOR THE TREATMENT OF PERIODONTAL DISEASE | Anacor Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080293675-A1 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTCALS INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1980564-A1 | Antibiotics containing borinic acid complexes and methods of use | Anacor Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7393856-B2 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7390806-B2 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080146803-A1 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. | 2008-06-19 | — | — | US | disclosed |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| WO-2006007384-A2 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| US-20060009422-A1 | Boron-containing compounds and methods of use | ANACOR PHARMACEUTICALS, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005123094-A2 | TREATMENT OR PREVENTION OF SKIN CONDITIONS OR TISSUE CONDITIONS IN ANIMALS USING BORYLOXYPYRIDYLMETHANONES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123095-A1 | ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| EP-1581500-A2 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | Anacor Pharmaceuticals, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20050070503-A1 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040224923-A1 | Antibiotics containing borinic acid complexes and methods of use | ANACOR PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
| WO-2004056322-A2 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224923-A1 | Antibiotics containing borinic acid complexes and methods of use | BPGM, BROX, TBCA | ENPP2 986/4885IDO1 1285/4885AGXT 1096/4885 |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | BPGM, HRH1, HRH3 | ENPP2 67/4885IDO1 1471/4885AGXT 1902/4885 |
| US-20060009422-A1 | Boron-containing compounds and methods of use | BROX, BTD, PBDC1 | ENPP2 1788/4885IDO1 2169/4885AGXT 1416/4885 |
| US-20080146803-A1 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | BPGM, BROX, TBCA | ENPP2 986/4885IDO1 1285/4885AGXT 1096/4885 |
| US-20050070503-A1 | Antibiotics containing borinic acid complexes and methods of use | BPGM, BROX, TBCA | ENPP2 986/4885IDO1 1285/4885AGXT 1096/4885 |
| US-20060019927-A1 | Anti-viral uses of borinic acid complexes | SSB, BPGM, HAVCR2 | ENPP2 420/4885IDO1 1452/4885AGXT 1781/4885 |
| US-20080293675-A1 | ANTIBIOTICS CONTAINING BORINIC ACID COMPLEXES AND METHODS OF USE | BPGM, BROX, TBCA | ENPP2 986/4885IDO1 1285/4885AGXT 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.